Overview
- Merck and Moderna said on Wednesday that a planned interim analysis of the Phase 3 INTerpath-001 trial met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival for intismeran given with Keytruda.
- The randomized trial enrolled about 1,137 patients with surgically resected stage IIB–IV melanoma who received either Keytruda plus the personalized mRNA vaccine or Keytruda alone for roughly one year.
- The companies reported no new safety signals and said adverse effects were consistent with prior studies and typical vaccine-type reactions.
- The study was halted at the first interim readout for efficacy so overall survival and full safety and subgroup details remain unresolved and will require longer follow-up and a full data release at a medical meeting.
- If regulators accept the detailed data the result could create a near-term approval and commercial path for individualized neoantigen mRNA therapies, but broad adoption will depend on manufacturing scale-up, reproducibility across other cancers, and long-term outcomes.